DermatologyNews.net

Dermatology Xagena

Patients with advanced melanoma, who have been treated with the monoclonal antibody, Ipilimumab ( Yervoy ), can survive for up to ten years, according to the largest analysis of overall survival for t ...


Psoriasis is a common and chronic immune-mediated inflammatory disease of the skin affecting approximately 2% of individuals of European descent with a strong genetic susceptibility. Classic lesions ...


Many patients with chronic idiopathic urticaria ( also called chronic spontaneous urticaria ) do not have a response to therapy with H1-antihistamines, even at high doses. In phase 2 trials, Omalizuma ...


The results from the head-to-head phase III FIXTURE study showing Secukinumab ( AIN457 ), an interleukin-17A ( IL-17A ) inhibitor, was significantly superior to Etanercept ( Enbrel ) in moderate-to-se ...


Nivolumab, a human immunoglobulin G4-blocking antibody against the T-cell programmed death-1 checkpoint protein, has activity against metastatic melanoma. Its safety, clinical efficacy, and correlativ ...


The European Commission has granted conditional approval to Erivedge ( Vismodegib ) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma ( BCC ) or locally advanced BCC ...


The results from the phase 3 trial in melanoma, which has evaluated the efficacy and safety of Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to trea ...


The statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30 mg BID monotherapy in both the ESTEEM 1 and 2 phase III studies. ESTEEM 1 ...


Researchers at Columbia University Medical Center ( CUMC; United States ) have devised a hair restoration method that can generate new human hair growth, rather than simply redistribute hair from one ...


Researchers from UCLA's Jonsson Comprehensive Cancer Center reported that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melan ...


Apremilast ( Otezla ), a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and doses of 20 mg twice daily ha ...


Phase II data, published in the New England Journal of Medicine ( NEJM ), have showen that Ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe p ...


The BRAF inhibitor Vemurafenib ( Zelboraf ) represents a new standard of care for metastatic melanoma patients with BRAF V600 mutations after showing improved progression free and overall survival in ...


Preliminary data from a pivotal phase 2 clinical trial of PLX4032 ( RG7204, Vemurafenib, Zelboraf ) in metastatic melanoma, showing significant tumor shrinkage in the majority of patients, are present ...


Raptiva ( Efalizumab ) is an immunosuppressive, humanized monoclonal antibody indicated for treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to ...